Jessica Jachimiec, MD
Family Medicine · Wasilla, AKNPI 1790964195
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 284 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,352 and has fallen 75.7% since, to $329 in 2025. Among family medicine clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$581
- Amgen$439
- Novartis$343
- GSK$304
- Pfizer$294
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,799100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $1,318 |
| AstraZeneca | 33 | $581 |
| Amgen | 25 | $439 |
| Novartis | 15 | $343 |
| GSK | 18 | $304 |
| Pfizer | 17 | $294 |
| Novo Nordisk | 17 | $281 |
| Lilly USA, LLC | 17 | $270 |
| Astellas Pharma US Inc | 9 | $215 |
| Merck | 10 | $174 |
| Mylan Specialty L.p. | 5 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $137 |
| Amarin Pharma, Inc. | 7 | $125 |
| Intuitive Surgical | 1 | $105 |
| Otsuka America Pharmaceutical, Inc. | 1 | $95 |
| Bayer | 4 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $90 |
| Boehringer Ingelheim | 3 | $68 |
| Johnson & Johnson | 3 | $63 |
| Sanofi Pasteur Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Eisai Inc. | 4 | $55 |
| Sanofi-aventis U.S. LLC | 2 | $53 |
| Inspire Medical Systems, Inc. | 3 | $51 |
| Bard Peripheral Vascular, Inc. | 1 | $49 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Exact Sciences | 2 | $40 |
| Genentech USA, Inc. | 2 | $40 |
| BD | 1 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Neurelis, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Organogenesis Inc. | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| UCB, Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$122
- Humira$113
- Rinvoq$113
- ENTRESTO$113
- Da Vinci Surgical System$105
How this compares
$5,799 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $53,007 |
| MounjaroTirzepatide | 23 | $29,741 |
| TrulicityDulaglutide | 15 | $21,243 |
| MyrbetriqMirabegron | 21 | $18,847 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,521 |
| XareltoRivaroxaban | 29 | $10,448 |
| EliquisApixaban | 12 | $9,464 |
| Rosuvastatin Calcium | 37 | $2,645 |
| Sevelamer Carbonate | 17 | $1,513 |
| Atorvastatin Calcium | 144 | $1,442 |
| Gabapentin | 81 | $1,438 |
| Clonidine | 12 | $1,326 |
| Levothyroxine Sodium | 87 | $872 |
| Ventolin HfaAlbuterol Sulfate | 11 | $810 |
| Losartan Potassium | 70 | $774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $281 | $53,00727 claims |
| Lilly USA, LLCMounjaro, Trulicity | $270 | $50,98438 claims |
| Astellas Pharma US IncMyrbetriq | $215 | $18,84721 claims |
| GSKTrelegy Ellipta | $304 | $11,52114 claims |
| Johnson & JohnsonXarelto | $63 | $10,44829 claims |
| PfizerEliquis | $294 | $9,46412 claims |
| AbbVieSynthroid | $1,318 | $70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.
Other family medicine in Wasilla
- Ray KelleyWasilla$9K
- Frank GreathouseWasilla$7K
- Jim CookWasilla$6K
- Tracy SlagerWasilla$5K
- Joyce RestadWasilla$5K
- Wade EricksonWasilla$3K
- Valerie KrozelWasilla$3K
- Sarah HennemannWasilla$3K
- Nathan GeorgeWasilla$3K
- Jaron MinerWasilla$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.